TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21624491

Group type: EXPERIMENTAL
Intervention: AZD1236 75 mg, twice daily for 6 weeks
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 17487212

Group type: EXPERIMENTAL
Intervention: Low-fat (20% of energy), high-fiber (18 g per 1000 kcals of energy intake), high-fruit and -vegetable (5-8 servings per day) dietary intervention
Number of subjects: 750

Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber, high-fruit and -vegetable dietary intervention (in lean subjects only)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Control group (in lean subjects only)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber, high-fruit and -vegetable dietary intervention
Number of subjects: 750
Study: 16636357

Group type: EXPERIMENTAL
Intervention: CPR+AED
Number of subjects: 1260

Group type: COMPARATOR
Intervention: CPR
Number of subjects: 1260
Study: 12955427

Group type: COMPARATOR
Intervention: 1-month clopidogrel therapy (75 mg p.o. for 1 month)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: 6-month clopidogrel therapy (75 mg p.o. for 6 months)
Number of subjects: 278
Study: 11149434

Group type: EXPERIMENTAL
Intervention: Circulatory occlusion by tourniquet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Exsanguination
Number of subjects: 18
Study: 9410298

Group type: EXPERIMENTAL
Intervention: Children with wheezing
Number of subjects: 53

Group type: COMPARATOR
Intervention: Randomized school children
Number of subjects: 53

Group type: COMPARATOR
Intervention: Asthmatic children
Number of subjects: 53
Study: 1583761

Group type: EXPERIMENTAL
Intervention: Active compression-decompression (ACD) CPR
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mechanical Thumper CPR
Number of subjects: 10
Study: 3896657

Group type: EXPERIMENTAL
Intervention: Piretanide (6 mg) once daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Furosemide (40 mg) once daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Piretanide (6 mg) twice daily at 08.00 and 20.00 hours
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Piretanide (6 mg) twice daily at 08.00 and 12.00 hours or 08.00 and 20.00 hours
Number of subjects: 8
Study: 30967321

Group type: EXPERIMENTAL
Intervention: Shared Decision-Making (SDM) intervention
Number of subjects: 202

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 202
Study: 30555463

Group type: EXPERIMENTAL
Intervention: Novel vaccine approaches for malaria
Number of subjects: 0
Study: 27038798

Group type: EXPERIMENTAL
Intervention: Communication training for primary care physicians
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Communication training plus access to an evidence-based point-of-care tool
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 25424793

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV23)
Number of subjects: 339

Group type: COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Both PPV23 and PCV7
Number of subjects: 339
Study: 22289113

Group type: EXPERIMENTAL
Intervention: Rizatriptan ODT 5mg (for <40kg group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rizatriptan ODT 10mg (for ≥40kg group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (for <40kg group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (for ≥40kg group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison with historical adult data
Number of subjects: 0
Study: 20140405

Group type: EXPERIMENTAL
Intervention: Cognitive treatment of illness perceptions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 17922666

Group type: EXPERIMENTAL
Intervention: TNF antagonists
Number of subjects: 0
Study: 15699801

Group type: EXPERIMENTAL
Intervention: Anterior fusion with instrumentation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Posterior spine fusion
Number of subjects: 43
Study: 11936912

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg/day for 3 days; n = 133)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo (n = 132)
Number of subjects: 265
Study: 10325453

Group type: EXPERIMENTAL
Intervention: 5 mg donepezil
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: 10 mg donepezil
Number of subjects: 818

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 818
Study: 8545142

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) codeine (mean daily dose: 273 ± 78 mg, range: 200-400 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) codeine
Number of subjects: 46
Study: 1426661

Group type: EXPERIMENTAL
Intervention: Ribomunyl treatment (4 days) with amoxicillin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 6362416

Group type: EXPERIMENTAL
Intervention: Ritodrine plus magnesium sulfate
Number of subjects: 41

Group type: COMPARATOR
Intervention: Ritodrine alone
Number of subjects: 41
Study: 31198455

Group type: EXPERIMENTAL
Intervention: Acupressure at PC6 and REN12 points
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 30531133

Group type: EXPERIMENTAL
Intervention: Ixazomib/lenalidomide/dexamethasone (IRd)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo-Rd
Number of subjects: 41
Study: 27312745

Group type: EXPERIMENTAL
Intervention: Horizontal bed rest (BR)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Seated position (SP)
Number of subjects: 32
Study: 24955552

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 59
Study: 22688670

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 40
Study: 20560941

Group type: EXPERIMENTAL
Intervention: 400 microg misoprostol
Number of subjects: 3005

Group type: EXPERIMENTAL
Intervention: 800 microg misoprostol
Number of subjects: 3005

Group type: EXPERIMENTAL
Intervention: Vaginal administration
Number of subjects: 3005

Group type: EXPERIMENTAL
Intervention: Sublingual administration
Number of subjects: 3005

Group type: EXPERIMENTAL
Intervention: Vaginal and sublingual routes
Number of subjects: 3005
Study: 18633051

Group type: EXPERIMENTAL
Intervention: Intraarticular midazolam 50 mug/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intraarticular midazolam 75 mug/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 60
Study: 16111487

Group type: EXPERIMENTAL
Intervention: Telephone invitation
Number of subjects: 235
Study: 12098721

Group type: EXPERIMENTAL
Intervention: Vitamin E 500 IU daily for four years
Number of subjects: 1193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1193
Study: 10084439

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) for 60 minutes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo stimulation for 60 minutes
Number of subjects: 30
Study: 8926604

Group type: EXPERIMENTAL
Intervention: Psychotherapy trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug trials
Number of subjects: 0
Study: 2391627

Group type: EXPERIMENTAL
Intervention: Florida Probe
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Conventional Probe
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Florida Disk Probe (double passes)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Florida Disk Probe (single passes)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Conventional Probe (single passes)
Number of subjects: 10

Group type: COMPARATOR
Intervention: All instruments
Number of subjects: 10
Study: 7036275

Group type: EXPERIMENTAL
Intervention: E3 protocol (12 patients)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: E76 protocol (11 patients)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Radiotherapy (60 Gy)
Number of subjects: 23
Study: 30508516

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Training (A+R)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study: 30251369

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d (n=1,467)
Number of subjects: 2867

Group type: COMPARATOR
Intervention: Usual care (n=1,400)
Number of subjects: 2867
Study: 27310331

Group type: EXPERIMENTAL
Intervention: Fevipiprant (QAW039)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24192386

Group type: EXPERIMENTAL
Intervention: Cervical CMV detection during pregnancy
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Maternal breast milk CMV levels
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Maternal CD4 < 450 cells/mm(3)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Each log10 increase in breast milk CMV
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Breast milk CMV level required for 50% probability of CMV transmission
Number of subjects: 147
Study: 23326213

Group type: EXPERIMENTAL
Intervention: Whey protein lycosome formulation (WPL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control groups (lycopene, WP singular formulation, placebo)
Number of subjects: 40
Study: 19385712

Group type: EXPERIMENTAL
Intervention: Duloxetine 20-60 mg/day orally, once or twice daily (up to 120 mg/day)
Number of subjects: 594

Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 594
Study: 17582663

Group type: EXPERIMENTAL
Intervention: Running footwear
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Off-the-shelf orthopaedic footwear
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control footwear
Number of subjects: 20
Study: 15310635

Group type: EXPERIMENTAL
Intervention: Low-dose IT lidocaine (15 mg) and sufentanil (10 microg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: IT lidocaine (50 mg)
Number of subjects: 49
Study: 11782985

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 9638713

Group type: EXPERIMENTAL
Intervention: Spiral Gold oxygenator
Number of subjects: 26

Group type: COMPARATOR
Intervention: Univox Gold oxygenator
Number of subjects: 26
Study: 8208894

Group type: EXPERIMENTAL
Intervention: Clonidine (1.5 microgram/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18
Study: 2913776

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Prazosin + Hydrochlorothiazide
Number of subjects: 27

Group type: COMPARATOR
Intervention: Atenolol + Hydrochlorothiazide
Number of subjects: 27
Study: 30449812

Group type: EXPERIMENTAL
Intervention: rTM alone
Number of subjects: 56

Group type: COMPARATOR
Intervention: rTM+AT
Number of subjects: 56
Study: 29214616

Group type: EXPERIMENTAL
Intervention: 3 grams OptiMSM methylsulfonylmethane
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 25268878

Group type: EXPERIMENTAL
Intervention: Curcuminoids (500 mg TID per oral)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Curcuminoids
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 23778938

Group type: EXPERIMENTAL
Intervention: Intanza/IDflu (9 µg for 18-59 y, 15 µg for ≥ 60 y)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Trivalent intramuscular vaccine (Vaxigrip(®) 15 µg)
Number of subjects: 240
Study: 20722532

Group type: EXPERIMENTAL
Intervention: Hard-bristled toothbrushes
Number of subjects: 120

Group type: COMPARATOR
Intervention: Soft-bristled toothbrushes
Number of subjects: 120

Group type: COMPARATOR
Intervention: Medium-bristled toothbrushes
Number of subjects: 120
Study: 19336629

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) in addition to fixed appliance therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fixed appliances only
Number of subjects: 19
Study: 16850439

Group type: EXPERIMENTAL
Intervention: Synchronized nasal intermittent positive pressure ventilation (SNIPPV) at 12 cmH(2)O
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Synchronized nasal intermittent positive pressure ventilation (SNIPPV) at 14 cmH(2)O
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP) at 5 cmH(2)O
Number of subjects: 15
Study: 15175203

Group type: EXPERIMENTAL
Intervention: HEADSS chart stamp intervention during a four-week phase
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control phase with no chart stamp during a six-week phase
Number of subjects: 306
Study: 10917181

Group type: COMPARATOR
Intervention: Hypertonic saline-epinephrine (HSE)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Histoacryl (N-butyl-2-cyanoacrylate)
Number of subjects: 126
Study: 9247755

Group type: EXPERIMENTAL
Intervention: ACE inhibitor-based treatment
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Diuretic-based treatment
Number of subjects: 6000
Study: 8100928

Group type: EXPERIMENTAL
Intervention: 2.5 mg rhDNase twice daily for 10 days
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 71
Study: 3493794

Group type: EXPERIMENTAL
Intervention: Propofol 3 mg kg‐1
Number of subjects: 2

Group type: COMPARATOR
Intervention: Methohexitone 2 mg kg‐1
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 2
Study: 28606702

Group type: EXPERIMENTAL
Intervention: Hazelnuts with skin (HZN+S)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Hazelnuts without skin (HZN-S)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Dietary advices for hyperlipidemia only (Control)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Hazelnuts (HZN)
Number of subjects: 66
Study: 27574999

Group type: EXPERIMENTAL
Intervention: Ventilation during delayed cord clamping (V‐DCC)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Delayed cord clamping alone (DCC only)
Number of subjects: 230
Study: 24597465

Group type: EXPERIMENTAL
Intervention: 500 mg TG hydrochloride
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1000 mg TG hydrochloride
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1500 mg TG hydrochloride
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 500 mg TG hydrochloride (multiple doses every 12h for 5 days)
Number of subjects: 24
Study: 23139970

Group type: EXPERIMENTAL
Intervention: Tubeless drainage (Group B)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional large-bore nephrostomy tube drainage (Group A)
Number of subjects: 54
Study: 21092220

Group type: EXPERIMENTAL
Intervention: Artemether‐lumefantrine (AL)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Artesunate‐amodiaquine (AA)
Number of subjects: 193
Study: 18956276

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (initially 25 microg, followed by 50 microg and 100 microg every 4 hours)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Vaginal dinoprostone (3 mg every 6 hours)
Number of subjects: 224
Study: 15654934

Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for 27.9±20.1 weeks
Number of subjects: 113
Study: 12892550

Group type: EXPERIMENTAL
Intervention: Audit of clinical charts with evaluation of clinical severity and adherence to explicit criteria of quality of inpatient care in OCFA.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Quality of care scale score.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Not applicable (control group).
Number of subjects: 90
Study: 10651074

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a (3 million units subcutaneously, twice a week for 3 months)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (15 age- and sex-matched healthy adults)
Number of subjects: 22
Study: 8754409

Group type: EXPERIMENTAL
Intervention: Chronic glomerulonephritis without nephrotic syndrome (NS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chronic glomerulonephritis with nephrotic syndrome (NS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients showing SPA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patients with CGN and CGN+NS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with SPA
Number of subjects: 60
Study: 1845847

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 IV day 1 and etoposide 120 mg/m2 IV days 1, 2, and 3
Number of subjects: 83

Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 IV day 1 and etoposide 120 mg/m2 IV day 1 and 240 mg/m2 orally days 2 and 3
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: IV etoposide regimen
Number of subjects: 83
Study: 6353336

Group type: EXPERIMENTAL
Intervention: Cefazoline (500 mg intramuscular every 8 hours for 6 doses)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (800 mg sulfametoxazole and 160 mg trimetoprime intramuscular every 12 hours for 6 doses)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 91
Study: 30777064

Group type: EXPERIMENTAL
Intervention: Manual therapy (MT) and stabilizing exercises (SEs)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Stabilizing exercises (SEs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Home exercises
Number of subjects: 60
Study: 29055680

Group type: EXPERIMENTAL
Intervention: 24 IU intranasal OXT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25845530

Group type: EXPERIMENTAL
Intervention: Peer-based HIV prevention intervention
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 227
Study: 23890374

Group type: EXPERIMENTAL
Intervention: Fermented milk containing Lactobacillus casei strain Shirota (LcS)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo drinks
Number of subjects: 154
Study: 21489741

Group type: EXPERIMENTAL
Intervention: Motivational interviewing integrated with social network counseling
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 28
Study: 19035970

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Prucalopride 4 mg
Number of subjects: 641

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Prucalopride
Number of subjects: 641
Study: 17341781

Group type: EXPERIMENTAL
Intervention: GuardWire distal protection device during PCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCI without distal protection (Control)
Number of subjects: 0
Study: 15899441

Group type: EXPERIMENTAL
Intervention: Artisan phakic intraocular lens (IOL) implantation
Number of subjects: 87

Group type: COMPARATOR
Intervention: Crystalline lens rise measurement
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Crystalline lens rise as a safety criterion
Number of subjects: 87
Study: 11912561

Group type: EXPERIMENTAL
Intervention: Psyllium (15 g PSY/d)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (cookies)
Number of subjects: 68
Study: 9698665

Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Selenium plus vitamins A, C, and E
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 8880382

Group type: EXPERIMENTAL
Intervention: Intramuscular and intralesional beta-interferon treatment
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Intramuscular beta-interferon treatment
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Intralesional beta-interferon treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 49
Study: 2114628

Group type: EXPERIMENTAL
Intervention: Almitrin (75 mg acute administration)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Almitrin (3 x 25 mg for 6 months)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Almitrin (75 mg additional administration)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 26
Study: 376578

Group type: EXPERIMENTAL
Intervention: Gerovital
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31097067

Group type: EXPERIMENTAL
Intervention: Drug-resistant tuberculosis (DR-TB) patients
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Increased BMI
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: CVD risk score
Number of subjects: 900
Study: 28103819

Group type: EXPERIMENTAL
Intervention: Telbivudine (600 mg/day)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Entecavir (0.5 mg/day)
Number of subjects: 97
Study: 26016867

Group type: EXPERIMENTAL
Intervention: Krill and salmon oil (KS oil), 5 1-g capsules for 8 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (canola oil), 5 1-g capsules for 8 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Krill and salmon oil (KS oil) after controlling for blood EPA and DHA levels
Number of subjects: 47
Study: 23287748

Group type: EXPERIMENTAL
Intervention: Electromagnetic (EM) navigationally assisted insertion without fluoroscopy (SureShot; Smith & Nephew)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard fluoroscopic assistance (OEC 9900; G.E. HealthCare)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both groups (EM and fluoroscopic)
Number of subjects: 101
Study: 20926968

Group type: EXPERIMENTAL
Intervention: 100-m time trial (TT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 400-m time trial (TT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 200-m time trial (TT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Heart Rate (HR)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rate of Perceived Dyspnea (RPD)
Number of subjects: 10